Irrus Investments

Novus Diagnostics is focused on developing an innovative diagnostic device that addresses sepsis, a life-threatening condition caused by infections. The company's technology enables rapid detection and classification of pathogens directly from whole blood samples. By providing quick and automated pathogen identification in just minutes, Novus Diagnostics aims to enhance the ability of healthcare providers to treat patients efficiently and effectively, while also maintaining cost-effectiveness in the diagnostic process.

Deciphex Limited, founded in 2017 and based in Dublin, Ireland, specializes in developing digital pathology software applications aimed at enhancing diagnostic workflows through artificial intelligence. The company offers two primary platforms: Patholytix and Diagnexia. Patholytix is designed for preclinical and toxicologic pathology, aiding pharmaceutical and clinical research organizations in optimizing safety assessments and accelerating drug development. Diagnexia facilitates rapid diagnostics by connecting global subspecialty pathologists, thereby addressing backlog issues. Both platforms automate routine tasks, allowing pathologists to concentrate on more complex cases, which ultimately leads to faster and more reliable diagnoses. Through its innovative approach, Deciphex is committed to improving patient outcomes and advancing healthcare delivery.

Bounce Insights is a digital consumer research platform that connects brands directly with consumers through a community of active respondents on its mobile app. The company specializes in delivering fast and robust quantitative research, offering a blend of research consultancy, data, and technology to support brands in their decision-making processes. By providing real-time access to consumer data and insights, Bounce Insights serves various industries, including consumer packaged goods, fast-moving consumer goods, retail, media, advertising, financial services, telecommunications, and e-commerce. This enables companies to gather essential consumer insights quickly, enhancing their ability to make informed decisions.

Ovagen is a biotechnology company specializing in the large-scale production of germ-free chicken eggs and birds, primarily for the pharmaceutical industry. The company's innovative process utilizes a transgenic chicken platform to produce recombinant proteins to Good Manufacturing Practice (GMP) standards. This technology provides pharmaceutical companies with a biosecure and flexible biomanufacturing solution for developing vaccines and therapeutic proteins. In addition to its core offerings, Ovagen also provides Contract Research Services and has expertise in specific poultry and rodent research technologies, as well as in SPF poultry and rodent housing and husbandry.

SymPhysis Medical focuses on developing innovative medical technologies aimed at treating chronic diseases, with an emphasis on enhancing patient experience and quality of life. The company's flagship product, releaze, addresses malignant pleural effusion (MPE), a common complication in late-stage cancer patients that can lead to severe shortness of breath and chest pain. This therapeutic device is designed for home use, effectively draining excess fluid from the pleural space. By utilizing an active component that enhances fluid removal efficiency, releaze alleviates distressing symptoms and improves treatment accessibility for patients requiring indwelling pleural catheter (IPC) therapies.

CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

SymPhysis Medical focuses on developing innovative medical technologies aimed at treating chronic diseases, with an emphasis on enhancing patient experience and quality of life. The company's flagship product, releaze, addresses malignant pleural effusion (MPE), a common complication in late-stage cancer patients that can lead to severe shortness of breath and chest pain. This therapeutic device is designed for home use, effectively draining excess fluid from the pleural space. By utilizing an active component that enhances fluid removal efficiency, releaze alleviates distressing symptoms and improves treatment accessibility for patients requiring indwelling pleural catheter (IPC) therapies.

FeelTect is a medical device company based in Galway, Ireland, founded in 2019. The company specializes in developing and marketing a connected-health technology known as Tight Alright, which is designed to measure and monitor sub-bandage pressure during compression therapy for venous leg ulcers (VLUs). This technology addresses a critical challenge in VLU treatment, as improper pressure application can lead to ineffective or dangerous outcomes. By providing live readings and recorded data, FeelTect's device allows both patients and healthcare providers to ensure that compression therapy is applied safely and effectively, ultimately facilitating optimal, individualized treatment regimens. The innovation not only enhances patient care but also aims to reduce the economic burden associated with VLU management.

Bluedrop Medical, established in 2014 and headquartered in Galway, Ireland, specializes in the development, manufacturing, and commercialization of an IoT-enabled device for early detection of diabetic foot ulcers. Their home-based system scans patients' feet daily, transmitting data to the cloud for analysis via advanced algorithms, which can identify skin abnormalities. This innovative solution aims to reduce the risk of amputation and improve the lives of diabetic patients, with a significant potential market given that up to 25% of diabetics may develop foot ulcers.

ByoWave is a company focused on creating inclusive gaming experiences through its innovative Proteus Controller, a modular video game controller designed for both disabled and non-disabled gamers. The controller features a unique 'snap and play' system, allowing users to easily connect various components and customize their gaming experience. ByoWave provides an online platform where users can build their own controller configurations and share them with the gaming community, ensuring accessibility and personal preference in gameplay. This approach not only enhances the gaming experience for individuals with disabilities but also fosters a collaborative environment for all gamers.

Ovagen is a biotechnology company specializing in the large-scale production of germ-free chicken eggs and birds, primarily for the pharmaceutical industry. The company's innovative process utilizes a transgenic chicken platform to produce recombinant proteins to Good Manufacturing Practice (GMP) standards. This technology provides pharmaceutical companies with a biosecure and flexible biomanufacturing solution for developing vaccines and therapeutic proteins. In addition to its core offerings, Ovagen also provides Contract Research Services and has expertise in specific poultry and rodent research technologies, as well as in SPF poultry and rodent housing and husbandry.

Hooke Bio Ltd., established in 2014 and located in Shannon, Ireland, specializes in developing microfluidic-based technologies for drug screening and related applications. The company has created a fully integrated high throughput screening system that focuses on 3D microtissues, including spheroids, organoids, and mini-organs. Its patented Mera technology generates biological data from these microtissues, aiming to minimize the use of animal models in preclinical studies and expedite drug development processes. Hooke Bio’s innovations facilitate the creation of more accurate disease models for testing new drugs and enable the testing of existing therapies using patient-specific disease samples, ultimately enhancing the ability of medical professionals to treat patients effectively.

Cinclus Pharma AG is a clinical-stage biotechnology company based in Basel, Switzerland, specializing in the development of small molecules for the treatment of gastric acid-related diseases, particularly gastroesophageal reflux disease (GERD). The company's lead asset, X842, is designed for patients suffering from severe erosive GERD, a condition for which effective treatment options are limited. In addition to X842, Cinclus Pharma is exploring a dual therapy approach that combines an antibiotic targeting Helicobacter pylori, a bacterium associated with gastric and duodenal mucosal issues. The company's research efforts aim to address significant unmet medical needs in the treatment of these conditions.

Deciphex Limited, founded in 2017 and based in Dublin, Ireland, specializes in developing digital pathology software applications aimed at enhancing diagnostic workflows through artificial intelligence. The company offers two primary platforms: Patholytix and Diagnexia. Patholytix is designed for preclinical and toxicologic pathology, aiding pharmaceutical and clinical research organizations in optimizing safety assessments and accelerating drug development. Diagnexia facilitates rapid diagnostics by connecting global subspecialty pathologists, thereby addressing backlog issues. Both platforms automate routine tasks, allowing pathologists to concentrate on more complex cases, which ultimately leads to faster and more reliable diagnoses. Through its innovative approach, Deciphex is committed to improving patient outcomes and advancing healthcare delivery.

Gasgon Medical is a medical device company focused on enhancing intravenous (IV) infusion processes to improve patient outcomes and support healthcare professionals. The company develops innovative devices aimed at optimizing clinical efficiency and reducing risks associated with IV administration, such as Vascular Air Embolism. By addressing the challenges faced by clinicians in delivering IV medicine, Gasgon Medical seeks to foster a future where all IV treatments can be administered with confidence, ultimately aiming to elevate the standard of care in healthcare settings.

CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

Bluedrop Medical, established in 2014 and headquartered in Galway, Ireland, specializes in the development, manufacturing, and commercialization of an IoT-enabled device for early detection of diabetic foot ulcers. Their home-based system scans patients' feet daily, transmitting data to the cloud for analysis via advanced algorithms, which can identify skin abnormalities. This innovative solution aims to reduce the risk of amputation and improve the lives of diabetic patients, with a significant potential market given that up to 25% of diabetics may develop foot ulcers.

Using the latest in-house technology Allview Healthcare gives you access to leading Consultant and surgical services Rapid diagnosis and care. Currently the largest dermatology provider across Ireland, servicing both the HSE (State Health Provider) and the VHI (Ireland's largest private insurance company) A highly experienced management team and board of directors with both medical and technical professionals whose main aim is to ensure that patients receive the best care by the best consultant at the right time. We work hard to ensure our best practice, clinical governance and quality assurance is at its highest level thus leading to extremely high patient satisfaction.

Sigrid Therapeutics AB, based in Stockholm, Sweden, is a clinical-stage biotechnology company focused on developing innovative therapeutic products aimed at preventing and treating lifestyle diseases. The company utilizes a novel materials platform technology, which consists of engineered minerals, to create an ingested medical device designed to lower blood sugar levels in prediabetic individuals. This lead product represents a new class of therapies that works in the gut to improve digestion and metabolic health, thereby assisting in weight loss and helping individuals manage chronic conditions associated with modern lifestyles.

AniV8 is a company focused on developing clinical sensor technology aimed at diagnosing and monitoring diseases in companion animals. Its innovative technology leverages clinical data alongside a specialized algorithm to assess motion, which helps veterinarians evaluate the effects of osteoarthritis pain in pets. By providing actionable insights into animal health, AniV8 aims to enhance veterinary care and improve the quality of life for companion animals.

Qualus is a provider of sustainable solutions for the leather industry, focused on reducing the environmental impact of leather tanneries. The company has developed a technology that employs Sferes, which are small polymer granules designed to help tanneries save water, lower production costs, and enhance the quality of leather. By integrating this technology, Qualus enables its customers to decrease their energy consumption and carbon footprint while also lowering operational expenses. Recently, the company secured £3 million in financing from Irrus Investments, along with co-investments from CPI Enterprises and angel investors from Cambridge Capital Group and Harvard Business School Alumni Angels of London.

Deciphex Limited, founded in 2017 and based in Dublin, Ireland, specializes in developing digital pathology software applications aimed at enhancing diagnostic workflows through artificial intelligence. The company offers two primary platforms: Patholytix and Diagnexia. Patholytix is designed for preclinical and toxicologic pathology, aiding pharmaceutical and clinical research organizations in optimizing safety assessments and accelerating drug development. Diagnexia facilitates rapid diagnostics by connecting global subspecialty pathologists, thereby addressing backlog issues. Both platforms automate routine tasks, allowing pathologists to concentrate on more complex cases, which ultimately leads to faster and more reliable diagnoses. Through its innovative approach, Deciphex is committed to improving patient outcomes and advancing healthcare delivery.

CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

Deciphex Limited, founded in 2017 and based in Dublin, Ireland, specializes in developing digital pathology software applications aimed at enhancing diagnostic workflows through artificial intelligence. The company offers two primary platforms: Patholytix and Diagnexia. Patholytix is designed for preclinical and toxicologic pathology, aiding pharmaceutical and clinical research organizations in optimizing safety assessments and accelerating drug development. Diagnexia facilitates rapid diagnostics by connecting global subspecialty pathologists, thereby addressing backlog issues. Both platforms automate routine tasks, allowing pathologists to concentrate on more complex cases, which ultimately leads to faster and more reliable diagnoses. Through its innovative approach, Deciphex is committed to improving patient outcomes and advancing healthcare delivery.

Hooke Bio Ltd., established in 2014 and located in Shannon, Ireland, specializes in developing microfluidic-based technologies for drug screening and related applications. The company has created a fully integrated high throughput screening system that focuses on 3D microtissues, including spheroids, organoids, and mini-organs. Its patented Mera technology generates biological data from these microtissues, aiming to minimize the use of animal models in preclinical studies and expedite drug development processes. Hooke Bio’s innovations facilitate the creation of more accurate disease models for testing new drugs and enable the testing of existing therapies using patient-specific disease samples, ultimately enhancing the ability of medical professionals to treat patients effectively.

ProVerum Medical is a medtech company focused on developing innovative minimally invasive devices for the treatment of benign prostatic hyperplasia (BPH). Its technology offers a safer and more effective approach to BPH treatment, allowing patients to receive care in a doctor's office or operating room with reduced invasiveness compared to traditional methods. The device addresses the enlargement of the prostate gland, which can lead to urinary difficulties, by being placed inside the urethra to restore normal urinary function. This advancement enables healthcare providers to offer improved treatment options for patients suffering from this condition.

OncoMark Limited, founded in 2007 and based in Dublin, Ireland, specializes in the discovery and development of diagnostic tools and therapeutic targets for cancer patients. The company focuses on companion diagnostic tests that assist pharmaceutical firms in selecting patients who are most likely to benefit from specific cancer treatments, thereby optimizing the drug development process and improving clinical trial outcomes. OncoMark's product offerings include tissue-based biomarker assays for pharmacodynamic and patient stratification studies, as well as a Biomarker Interpretation Workflow platform that automates various analytical processes. The company is developing a portfolio of diagnostic tests for key cancer types, including breast, colorectal, prostate, and melanoma, supported by substantial EU R&D funding. With a small team and a strong advisory board, OncoMark aims to enhance patient care by providing tools that facilitate more effective treatment decisions based on genetic markers and other biomarkers.

ProVerum Medical is a medtech company focused on developing innovative minimally invasive devices for the treatment of benign prostatic hyperplasia (BPH). Its technology offers a safer and more effective approach to BPH treatment, allowing patients to receive care in a doctor's office or operating room with reduced invasiveness compared to traditional methods. The device addresses the enlargement of the prostate gland, which can lead to urinary difficulties, by being placed inside the urethra to restore normal urinary function. This advancement enables healthcare providers to offer improved treatment options for patients suffering from this condition.

Adama Innovations Ltd. is a company based in Dublin, Ireland, that specializes in developing nanotechnology solutions for advanced manufacturing. Founded in 2010 as a spin-out from CRANN, the nanotechnology institute at Trinity College Dublin, the company focuses on creating high-resolution patterns on ultra-hard materials. Its flagship product is a diamond-based nano-scale probe designed for atomic force microscopy (AFM), which allows for precise imaging, measurement, and manipulation at the nanoscale. These probes have diverse applications, including general topography, electrical analysis, and sidewall characterization. Additionally, Adama Innovations produces diamond sharp cones and flare-shaped probes for various metrology applications. The company’s technology also supports the manufacturing of medical devices by enhancing the capabilities of injection molds and forming dies, while contributing to labeling and anti-counterfeiting solutions.

Embo Medical, based at the National University of Ireland, specializes in the development of innovative medical devices for vascular embolization. Its flagship product, known as the Caterpillar, is designed to improve the efficiency of embolization procedures by allowing for superior and shorter procedural times. This device is intended for use in the peripheral vascular embolization market, which sees approximately 180,000 procedures conducted annually worldwide. Embo Medical aims to enhance the safety and cost-effectiveness of these important medical interventions, positioning itself as a key player in the field.

Wattics is a company focused on combating climate change through advanced software-as-a-service energy analytics. It provides a cloud-based data analytics platform designed for energy consultants, analysts, and managers, transforming energy management by replacing traditional spreadsheets with innovative solutions. This platform facilitates cost control and asset management while enabling energy professionals to offer new services, ultimately creating recurring revenue streams and enhancing customer acquisition and retention through automated reports and notifications. Wattics' software supports integration with various meter manufacturers, renewable energy sources, environmental sensors, and IoT devices, featuring machine learning analytics to identify energy anomalies. Users can create customized formulas to analyze savings and meet energy regulations and efficiency goals. Additionally, the MAESTRO plan allows firms to fully brand and personalize their analytics services, granting dashboard access to clients. Founded in 2011 by Antonio Ruzzelli and headquartered in Dublin, Wattics has expanded its support presence to New York, Treviso, and Berlin.